

Justification for the selection of a candidate CoRAP substance

Substance Name (Public Name):	methyl salicylate
Chemical Group:	
EC Number:	204-317-7
CAS Number:	119-36-8
Submitted by:	FRANCE
Published:	20/03/2013

NOTE

This document has been prepared by the evaluating Member State given in the CoRAP update.

Contents

1	IDENTITY OF THE SUBSTANCE	3
1.1	Name and other identifiers of the substance	3
2	CLASSIFICATION AND LABELLING	4
2.1	Harmonised Classification in Annex VI of the CLP.....	4
2.2	Proposal for Harmonised Classification in Annex VI of the CLP	4
2.3	Self classification	4
3	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE	5
3.1	Legal basis for the proposal	5
3.2	Grounds for concern	5
3.3	Information on aggregated tonnage and uses.....	5
3.4	Other completed/ongoing regulatory processes that may affect suitability for substance evaluation	6
3.5	Information to be requested to clarify the suspected risk.....	6
3.6	Potential follow-up and link to risk management.....	6

1 IDENTITY OF THE SUBSTANCE

1.1 Name and other identifiers of the substance

Table 1: Substance identity

Public Name:	methyl salicylate
EC number:	204-317-7
EC name:	methyl salicylate
CAS number (in the EC inventory):	119-36-8
CAS number:	119-36-8
CAS name:	Benzoic acid, 2-hydroxy-, methyl ester
IUPAC name:	Methyl 2-hydroxybenzoate
Index number in Annex VI of the CLP Regulation	
Molecular formula:	C ₈ H ₈ O ₃
Molecular weight or molecular weight range:	152.1473 g/mol
Synonyms:	


Type of substance:

Mono-constituent

Multi-constituent

UVCB

Structural formula:



2 CLASSIFICATION AND LABELLING

2.1 Harmonised Classification in Annex VI of the CLP

Not listed in Annex VI

2.2 Proposal for Harmonised Classification in Annex VI of the CLP

None

2.3 Self classification

The registration data includes the following self classification:

According to CLP criteria:

- Acute Tox. 4, H302: Harmful if swallowed.

According to DSD criteria:

- Xn; R22 Harmful; Harmful if swallowed.

In addition are the following classification(s) included in the Classification and Labelling Inventory:

- Eye Irrit. 2, H319: Causes serious eye irritation
- Skin Irrit. 2, H315: Causes skin irritation
- Repr. 2, H361: Suspected of damaging fertility or the unborn child
- STOT SE 3, H335: May cause respiratory irritation
- Repr. 1B, H360: May damage fertility or the unborn child
- Lact., H362: May cause harm to breast-fed children
- Eye Irrit. 2A, H319: Causes serious eye irritation

3 JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE

3.1 Legal basis for the proposal

Article 44(1) (refined prioritisation criteria for substance evaluation)

Article 45(5) (Member State priority)

3.2 Grounds for concern

<input checked="" type="checkbox"/> (Suspected) CMR	<input type="checkbox"/> Wide dispersive use	<input type="checkbox"/> Cumulative exposure
<input type="checkbox"/> (Suspected) Sensitiser	<input checked="" type="checkbox"/> Consumer use	<input type="checkbox"/> High RCR
<input type="checkbox"/> (Suspected) PBT	<input type="checkbox"/> Exposure of sensitive populations	<input checked="" type="checkbox"/> Aggregated tonnage
<input type="checkbox"/> Suspected endocrine disruptor	<input type="checkbox"/> Other (provide further details below)	
<p>Available data with MeS give hint that it could be embryofetotoxic. From the tremendous amount of data presented for read-across from aspirin and salicylic acid, the results of the key and supporting studies suggests that salicylic acid has embryofetotoxic effect in rats at doses not causing clear maternal toxicity, with evidence of malformations at maternally toxic doses (registration data). Therefore this point deserves to be evaluated.</p>		

3.3 Information on aggregated tonnage and uses

<input type="checkbox"/> 1 - 10 t	<input type="checkbox"/> 10 - 100 t	<input type="checkbox"/> 100 - 1000 t	<input checked="" type="checkbox"/> 1000 - 10,000 t	
<input type="checkbox"/> 10,000 - 100,000 t	<input type="checkbox"/> 100,000 - 1000,000 t	<input type="checkbox"/> > 1000,000 t	<input type="checkbox"/> Confidential	
<input checked="" type="checkbox"/> Industrial Use	<input checked="" type="checkbox"/> Professional Use	<input checked="" type="checkbox"/> Consumer Use	<input type="checkbox"/> Closed System	

3.4 Other completed/ongoing regulatory processes that may affect suitability for substance evaluation

<input type="checkbox"/> Compliance Check	<input type="checkbox"/> Annex VI (CLP)
<input type="checkbox"/> Testing Proposal(s)	<input type="checkbox"/> Annex XIV (Authorisation)
<input type="checkbox"/> Substance Identification Issues	<input type="checkbox"/> Annex XVII (Restriction)
<input type="checkbox"/> ESR Programme	<input type="checkbox"/> Other (provide further details below)

3.5 Information to be requested to clarify the suspected risk

<input checked="" type="checkbox"/> Information on toxicological properties	<input type="checkbox"/> Information on exposure
<input type="checkbox"/> Information on fate and behaviour	<input type="checkbox"/> Information on uses
<input type="checkbox"/> Information on ecotoxicological properties	<input type="checkbox"/> Other (provide further details below)
<input type="checkbox"/> Information on physico-chemical properties	
<p>Substance evaluation (targeted to reprotoxicity) would allow evaluating the tremendous amount of data available by read across with acetylsalicylic acid regarding the potential reproductive (developmental in particular) toxicity of MeS. Would those data be sufficient to clarify the concern (no need for classification or CLH report), the substance evaluation will end-up with no additional data requirement.</p>	

3.6 Potential follow-up and link to risk management

<input type="checkbox"/> Restriction	<input type="checkbox"/> Harmonised C&L
<input type="checkbox"/> Authorisation	<input type="checkbox"/> Other (provide further details below)
<p>To be determined following substance evaluation</p>	